Charles Schwab Investment Management Inc Kymera Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 354,106 shares of KYMR stock, worth $10.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
354,106
Previous 306,692
15.46%
Holding current value
$10.7 Million
Previous $7.81 Million
82.31%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding KYMR
# of Institutions
164Shares Held
63.1MCall Options Held
39.7KPut Options Held
9.7K-
Price T Rowe Associates Inc Baltimore, MD6.33MShares$192 Million0.03% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$181 Million3.05% of portfolio
-
Atlas Venture Life Science Advisors, LLC5.38MShares$163 Million27.05% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$156 Million6.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.77MShares$144 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $1.65B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...